OverviewSuggest Edit

Teligent is a specialty generic pharmaceutical company which develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products. The Company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The Company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services.

TypePublic
Founded1977
HQVineland, US
Websiteteligent.com
Employee Ratings2.7

Latest Updates

Employees (est.) (Dec 2018)189(+4%)
Job Openings13
Revenue (FY, 2018)$65.9 M(-2%)
Share Price (Jun 2019)$0.5 (-13%)

Key People/Management at Teligent

Jason Grenfell-Gardner

Jason Grenfell-Gardner

President & CEO
Damian Finio

Damian Finio

CFO
Peter Gallagher

Peter Gallagher

Vice President, Strategic Affairs
Shannon Johnston

Shannon Johnston

Vice President, Human Resources
Barbara Lani

Barbara Lani

Senior Vice President, Quality
Mark Mantel

Mark Mantel

General Manager, Canada
Show more

Teligent Office Locations

Teligent has offices in Vineland, Woodbridge Township, Tallinn and Mississauga
Vineland, US (HQ)
105 Lincoln Ave
Woodbridge Township, US
33 S Wood Ave #730, Iselin
Mississauga, CA
5995 Avebury Rd #804
Tallinn, EE
Akadeemia tee 21/5
Show all (4)

Teligent Financials and Metrics

Teligent Revenue

Teligent's revenue was reported to be $65.87 m in FY, 2018
USD

Revenue (Q1, 2019)

13.1m

Gross profit (Q1, 2019)

5.8m

Gross profit margin (Q1, 2019), %

43.9%

Net income (Q1, 2019)

(8.7m)

EBIT (Q1, 2019)

(2.7m)

Market capitalization (10-Jun-2019)

29.5m

Closing stock price (10-Jun-2019)

0.5

Cash (31-Mar-2019)

6.4m
Teligent's current market capitalization is $29.5 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

18.2m44.3m66.9m67.3m65.9m

Cost of goods sold

12.1m22.9m32.2m39.9m43.5m

Gross profit

6.1m21.3m34.7m27.4m22.4m

Gross profit Margin, %

34%48%52%41%34%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

4.0m6.9m6.5m6.7m10.7m8.9m11.6m15.7m17.1m16.2m19.9m18.4m12.9m14.5m16.2m18.3m13.1m

Cost of goods sold

2.7m4.0m3.6m4.0m5.0m5.2m5.5m7.7m7.6m8.1m9.0m10.4m10.3m9.3m11.5m11.6m7.4m

Gross profit

1.3m2.9m2.9m2.6m5.6m3.7m6.1m8.0m9.6m8.0m10.9m8.0m2.5m5.2m4.8m6.7m5.8m

Gross profit Margin, %

33%42%45%39%53%41%52%51%56%50%55%44%20%36%29%37%44%
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.1m87.2m66.0m26.7m9.7m

Accounts Receivable

4.9m14.0m21.7m18.1m

Inventories

2.9m9.0m12.7m16.1m16.3m

Current Assets

10.6m116.8m103.3m64.5m48.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

1.4m2.4m1.8m23.2m157.0m150.2m145.7m87.0m81.2m74.6m59.5m50.2m38.2m12.8m13.7m15.3m6.4m

Accounts Receivable

2.9m4.1m5.3m6.4m16.3m17.3m10.9m13.2m15.5m17.2m25.2m27.3m25.0m13.4m16.1m

Inventories

2.5m2.7m2.7m3.2m3.7m4.1m5.0m10.1m11.0m12.5m14.3m14.4m14.2m17.8m17.6m17.9m21.0m

Current Assets

7.1m9.9m10.6m33.8m178.4m173.1m163.0m117.7m110.6m106.9m101.9m95.0m79.8m46.6m49.5m51.4m45.8m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(84.0k)6.7m(12.0m)(15.2m)(36.3m)

Depreciation and Amortization

375.0k

Inventories

(1.2m)(3.6m)(5.0m)(5.3m)(1.9m)

Accounts Payable

2.5m(2.8m)4.7m5.7m(3.4m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(755.0k)167.0k(178.0k)(380.0k)6.6m15.9m13.0m(950.0k)(3.9m)(6.6m)831.0k(88.0k)(9.1m)(4.8m)(17.9m)(21.9m)(8.7m)

Depreciation and Amortization

280.0k93.0k185.0k292.0k

Inventories

(844.0k)194.0k32.0k(463.0k)(1.4m)(2.2m)(954.0k)(2.7m)(4.4m)(1.8m)(2.6m)(2.8m)(2.4m)(2.8m)(2.7m)(5.1m)

Accounts Payable

729.0k(1.1m)42.0k1.1m842.0k2.7m2.4m2.6m2.5m259.0k2.4m4.0m(11.8m)(4.1m)(6.9m)(95.0k)
USDY, 2019

Financial Leverage

18.8 x
Show all financial metrics

Teligent Online and Social Media Presence

Embed Graph

Teligent News and Updates

Teligent, Inc. to Present at the Raymond James Life Sciences and MedTech Conference on June 19th 2019

BUENA, N.J., June 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James Life Sciences and MedTech Conference June 19, 2019. The Conference is taking place June 18th - June 19th, 2019 at the L…

Teligent, Inc. Announces First Quarter 2019 Results

BUENA, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2019.

Teligent, Inc. to Hold Conference Call for First Quarter 2019 Results on Monday May 6th, 2019

BUENA, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday May 6th, 2019 to discuss the 1st  quarter 2019 financial results and business update.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm

NEW YORK, April 22, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...

Teligent Provides Update on Orphan Drug Complete Response Letter

BUENA, N.J., April 22, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that on April 16, 2019, its development partner has filed the response to the Complete Response Letter (“CRL”) it received on August 30th, 201…

Teligent, Inc. Management Comments on Recent Market Movements

BUENA, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today provided commentary on the recent market movements in the price of its stock.
Show more

Teligent Frequently Asked Questions

  • When was Teligent founded?

    Teligent was founded in 1977.

  • Who are Teligent key executives?

    Teligent's key executives are Jason Grenfell-Gardner, Damian Finio and Peter Gallagher.

  • How many employees does Teligent have?

    Teligent has 189 employees.

  • What is Teligent revenue?

    Latest Teligent annual revenue is $65.9 m.

  • What is Teligent revenue per employee?

    Latest Teligent revenue per employee is $348.5 k.

  • Who are Teligent competitors?

    Competitors of Teligent include Otonomy, Shire and Pharnext.

  • Where is Teligent headquarters?

    Teligent headquarters is located at 105 Lincoln Ave, Vineland.

  • Where are Teligent offices?

    Teligent has offices in Vineland, Woodbridge Township, Tallinn and Mississauga.

  • How many offices does Teligent have?

    Teligent has 4 offices.